DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 19-763/S-016

SUPPLEMENT APPROVAL

Baxter Healthcare Corporation
Attention: Rebecca Anne Ikusz
212 W. IL Rte 120
Round Lake, IL 60073

Dear Ms. Ikusz:

Please refer to your Supplemental New Drug Application (sNDA) dated April 3, 2008, received April 3, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Ifosfamide for Injection).

We acknowledge receipt of your amendments by email dated august 30, 2010 and March 18, 2011.

This "Prior Approval" supplemental new drug application provides for revisions 1) to the pharmacokinetics and Geriatric Use sections to add information on geriatric use and 2) revisions to the How Supplied sections, and references to update the references on safe handling section.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Alice Kacuba, Chief, Project Management Staff, at (301) 796-1381.

Sincerely,

{See appended electronic signature page}

Amna Ibrahim, M.D,
Deputy Director
Division of Drug Oncology Drug Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ALICE KACUBA
03/18/2011

AMNA IBRAHIM
03/23/2011